纳武利尤单抗在复发转移性鼻咽癌中的抗肿瘤活性:国际多中心II期研究
该国际多中心II期研究评估纳武利尤单抗在多次经治复发或转移性鼻咽癌患者中的抗肿瘤活性,共44例可评价,客观缓解率20.5%,1年总生存率59%,1年无进展生存率19.3%,未发现意外毒性,生物标志物结果需更大样本验证。
要点
- 纳武利尤单抗在多次经治复发转移鼻咽癌中ORR达20.5%,1年OS率59%。
- PD-L1表达与EBV DNA清除未显示与生存的统计学关联。
核心结论
- 纳武利尤单抗在复发或转移性鼻咽癌中显示有前景的抗肿瘤活性,1年总生存率与同类人群历史数据相比更优。
- 生物标志物结果仅为假设生成,需在更大队列中验证。
研究设计与样本
- 国际多中心II期研究(Mayo Clinic Phase 2 Consortium,NCI-9742),纳入多次经治的复发或转移性鼻咽癌患者,接受纳武利尤单抗治疗至疾病进展。
- 共44例患者可评价,主要终点为客观缓解率,次要终点包括生存和毒性。
主要发现
- 总体客观缓解率为20.5%(完全缓解1例,部分缓解8例)。
- 9例患者接受纳武利尤单抗治疗超过12个月(20%)。
- 1年总生存率为59%(95%CI,44.3%至78.5%),1年无进展生存率为19.3%(95%CI,10.1%至37.2%)。
- 客观缓解率与生物标志物无统计学相关性;描述性分析显示PD-L1阳性肿瘤(表达>1%)患者缓解比例高于PD-L1阴性肿瘤患者。
关键数值与推荐
- PD-L1阳性定义为肿瘤表达>1%。
临床怎么用
- 纳武利尤单抗可作为多次经治复发或转移性鼻咽癌患者的治疗选择之一,但需在随机研究中进一步评估。
- HLA I类分子表达缺失可能提示更优的无进展生存,但尚不能作为常规选择依据。
局限性
- 样本量较小(44例),为单臂II期研究,结论需随机研究验证。
- 生物标志物分析为探索性,结果仅为假设生成,需更大队列验证。
- PD-L1表达与EBV DNA清除未显示与生存的统计学关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose This multinational study evaluated the antitumor activity of nivolumab in nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were investigated in an exploratory analysis. Patients and Methods Patients with multiply pretreated recurrent or metastatic NPC were treated with nivolumab until disease progression. The primary end point was objective response rate (ORR) and secondary end points included survival and toxicity. The expression of programmed death-ligand 1 (PD-L1) and human leukocyte antigens A and B in archived tumors and plasma clearance of Epstein-Barr virus DNA were correlated with ORR and survival. Results A total of 44 patients were evaluated and the overall ORR was 20.5% (complete response, n = 1; partial response, n = 8). Nine patients received nivolumab for > 12 months (20%). The 1-year overall survival rate was 59% (95% CI, 44.3% to 78.5%) and 1-year progression-free survival (PFS) rate was 19.3% (95% CI, 10.1% to 37.2%). There was no statistical correlation between ORR and the biomarkers; however, a descriptive analysis showed that the proportion of patients who responded was higher among those with PD-L1 positive tumors (> 1% expression) than those with PD-L1-negative tumors. The loss of expression of one or both human leukocyte antigen class 1 proteins was associated with better PFS than when both proteins were expressed (1-year PFS, 30.9% v 5.6%; log-rank P = .01). There was no association between survival and PD-L1 expression or plasma Epstein-Barr virus DNA clearance. There was no unexpected toxicity to nivolumab. Conclusion Nivolumab has promising activity in NPC and the 1-year overall survival rate compares favorably with historic data in similar populations. Additional evaluation in a randomized setting is warranted. The biomarker results were hypothesis generating and validation in larger cohorts is needed.
引用
- Ma BBY, Lim WT, Goh BC, et al. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018. PMID: 29584545. doi:10.1200/JCO.2017.77.0388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。